Trial Profile
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2021
Price :
$35
*
At a glance
- Drugs Lusutrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shionogi
- 24 Feb 2021 Status changed from completed to discontinued.
- 13 May 2014 New trial record